Kyoto University: Providing iPS cells to Novo Nordisk: Macrophage research
Kyoto University iPS Cell Research Foundation:
For the first time, we will provide the HLA homo iPS cell stock (research strain) manufactured by our foundation to overseas pharmaceutical companies.
Novo Nordisk:
The provider, Novo Nordisk,
Headquartered in Denmark
Has affiliated companies in 80 countries around the world
Diabetes, obesity, hemophilia, failure to thrive, etc.
A global pharmaceutical company that develops therapeutic agents.
ES cell / cell bank production business:
One of our goals is to strengthen our efforts for stem cell therapy.
We are also working on the business of creating cell banks for ES cells.
Research on differentiation into macrophages:
At the discretion of the company, we received an application for the use of our foundation’s iPS cell stock.
In the study of differentiation into macrophages, it was judged that “iPS cells may be more suitable than ES cells.”
Official supplier certification:
Kyoto University iPS Cell Research Foundation, from Novo Nordisk
Certified as an official supplier of “HUMAN BIOSAMPLES IN PHARMACEUTICAL RESEARCH”.
https://www.cira-foundation.or.jp/2021/05/19-100029.html
Provision of HLA-homozygous iPS cellｓ to Novo Nordisk
Kyoto, Japan, May 19th, 2021
The CiRA Foundation® (“CiRA_F” located in Kyoto, Japan) and Novo Nordisk A/S (Denmark)
today announced that CiRA_F will provide HLA-homozygous iPS cell stock to Novo Nordisk.
Summary of the plans
1)Execution of contracts
Novo Nordisk and CiRA_F will proceed to formalize the agreement.
2)Research period at Novo Nordisk using our stock
From the arrival of the cells to December 31, 2025.
The iPS cells provided by CiRA_F
will be used for research on stem cell-based therapies if they are found suitable for use in the experiments conducted by Novo Nordisk after checking their stability and differentiation ability.